Skip to main navigation
Pharvaris N.V. Logo
  • Careers
  • Investors & Media
  • Contact
  • SCIENCE
  • PIPELINE
  • DISEASE FOCUS
  • HAE COMMUNITY
  • CLINICAL TRIALS
  • ABOUT US

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

ACAAI Annual Scientific Meeting 2022

Nov 10 - Nov 14, 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB
Pharvaris N.V. Logo

CONTACT US

FOLLOW US

linkedin logo

©2023 Pharvaris N.V. © All Rights Reserved

  • Privacy Policy
  • Terms of Use